{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:31:30Z","timestamp":1779143490186,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11657-019-0672-4","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T03:03:01Z","timestamp":1578020581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["No impact of anti-Rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Laurence","family":"Ferrieres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Degboe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline","family":"Ruyssen-Witrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"672_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0002-9343(99)00028-5","volume":"106","author":"P von der Recke","year":"1999","unstructured":"von der Recke P, Hansen MA, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106:273\u2013278","journal-title":"Am J Med"},{"key":"672_CR2","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/jbmr.3089","volume":"32","author":"N Veronese","year":"2017","unstructured":"Veronese N et al (2017) Relationship between low bone mineral density and fractures with incident cardiovascular disease: a systematic review and meta-analysis. J Bone Miner Res Off J Am Soc Bone Miner Res 32:1126\u20131135","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"672_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122646","volume":"10","author":"DH Kim","year":"2015","unstructured":"Kim DH et al (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One 10:e0122646","journal-title":"PLoS One"},{"key":"672_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","volume":"252","author":"G Kranenburg","year":"2016","unstructured":"Kranenburg G et al (2016) Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis 252:106\u2013115","journal-title":"Atherosclerosis"},{"key":"672_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL et al (2015) A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. Transl Endocrinol Metab 100:1335\u20131342","journal-title":"Transl Endocrinol Metab"},{"key":"672_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3349\/ymj.2016.57.4.905","volume":"57","author":"J-M Koh","year":"2016","unstructured":"Koh J-M et al (2016) Assessment of denosumab in Korean postmenopausal women with osteoporosis: randomized, double-blind, placebo-controlled trial with open-label extension. Yonsei Med J 57:905","journal-title":"Yonsei Med J"},{"key":"672_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung M, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"672_CR8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","volume":"23","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Shiraki M (2012) Dose\u2013response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int 23:1131\u20131140","journal-title":"Osteoporos Int"},{"key":"672_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, McClung M, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study Group (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229","journal-title":"Bone"},{"key":"672_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","volume":"26","author":"T Sugimoto","year":"2015","unstructured":"Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T (2015) Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the denosumab fracture intervention randomized placebo controlled trial (DIRECT). Osteoporos Int 26:765\u2013774","journal-title":"Osteoporos Int"},{"key":"672_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.bone.2014.04.015","volume":"64","author":"MR John","year":"2014","unstructured":"John MR, Harfst E, Loeffler J, Belleli R, Mason J, Bruin GJ, Seuwen K, Klickstein LB, Mindeholm L, Widler L, Kneissel M (2014) AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone 64:204\u2013210","journal-title":"Bone"},{"key":"672_CR12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s11999-015-4669-z","volume":"474","author":"M Bhandari","year":"2016","unstructured":"Bhandari M et al (2016) Does teriparatide improve femoral neck fracture healing: results from a randomized placebo-controlled trial. Clin Orthop 474:1234\u20131244","journal-title":"Clin Orthop"},{"key":"672_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722","journal-title":"JAMA"},{"key":"672_CR14","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"672_CR15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00774-008-0871-3","volume":"26","author":"A Miyauchi","year":"2008","unstructured":"Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T (2008) Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab 26:624\u2013634","journal-title":"J Bone Miner Metab"},{"key":"672_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1210\/jc.2009-0358","volume":"95","author":"F Cosman","year":"2010","unstructured":"Cosman F et al (2010) Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 95:151\u2013158","journal-title":"J Clin Endocrinol Metab"},{"key":"672_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","volume":"47","author":"A Miyauchi","year":"2010","unstructured":"Miyauchi A et al (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493\u2013502","journal-title":"Bone"},{"key":"672_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bone.2012.11.045","volume":"53","author":"K Henriksen","year":"2013","unstructured":"Henriksen K et al (2013) Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1\u201331)NH2] in postmenopausal women with osteoporosis. Bone 53:160\u2013166","journal-title":"Bone"},{"key":"672_CR19","doi-asserted-by":"crossref","unstructured":"Fujita, T., Fukunaga, M., Itabashi, A., Tsutani, K. & Nakamura, T. Once-weekly injection of low-dose teriparatide (28.2 \u03bcg) reduced the risk of vertebral fracture in patients with primary osteoporosis. Calcif. Tissue Int. 94, 170\u2013175 (2014)","DOI":"10.1007\/s00223-013-9777-8"},{"key":"672_CR20","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T et al (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1\u201334] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106","journal-title":"J Clin Endocrinol Metab"},{"key":"672_CR21","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbj\u00e6rg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung M, Bone HG, Ljunggren \u00d6, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E (2015) A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 100:1335\u20131342","journal-title":"J Clin Endocrinol Metab"},{"key":"672_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jbmr.2043","volume":"29","author":"EJ Samelson","year":"2014","unstructured":"Samelson EJ et al (2014) RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk: RANKL inhibition with denosumab and aortic calcification. J Bone Miner Res 29:450\u2013457","journal-title":"J Bone Miner Res"},{"key":"672_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1378\/chest.13-0675","volume":"144","author":"A Sharma","year":"2013","unstructured":"Sharma A et al (2013) Risk of serious atrial fibrillation and stroke with use of bisphosphonates. Chest 144:1311\u20131322","journal-title":"Chest"},{"key":"672_CR24","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.amjcard.2014.03.008","volume":"113","author":"A Sharma","year":"2014","unstructured":"Sharma A et al (2014) Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol 113:1815\u20131821","journal-title":"Am J Cardiol"},{"key":"672_CR25","doi-asserted-by":"crossref","unstructured":"Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA (2013) Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone 53:160\u2013166","DOI":"10.1016\/j.bone.2012.11.045"},{"key":"672_CR26","doi-asserted-by":"crossref","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","DOI":"10.1056\/NEJMoa074941"},{"key":"672_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00198-010-1411-2","volume":"22","author":"LA Beaupre","year":"2011","unstructured":"Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983\u2013991","journal-title":"Osteoporos Int"},{"key":"672_CR28","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00198-010-1444-6","volume":"22","author":"PN Sambrook","year":"2011","unstructured":"Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ (2011) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22:2551\u20132556","journal-title":"Osteoporos Int"},{"key":"672_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jamda.2009.12.004","volume":"11","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Arora T, Matthews RS, Taylor A, Becker DJ, Colon-Emeric C, Kilgore ML, Morrisey MA, Saag KG, Safford MM, Warriner A, Delzell E (2010) Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc 11:584\u2013591","journal-title":"J Am Med Dir Assoc"},{"key":"672_CR30","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jc.2009-0852","volume":"95","author":"MJ Bolland","year":"2010","unstructured":"Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174\u20131181","journal-title":"J Clin Endocrinol Metab"},{"key":"672_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/CIRCRESAHA.110.216846","volume":"107","author":"MK Osako","year":"2010","unstructured":"Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H, Shimamura M, Miyake T, Rakugi H, Morishita R (2010) Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 107:466\u2013475","journal-title":"Circ Res"},{"key":"672_CR32","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/eurheartj\/ehq109","volume":"31","author":"S Pilz","year":"2010","unstructured":"Pilz S et al (2010) Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 31:1591\u20131598","journal-title":"Eur Heart J"},{"key":"672_CR33","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1161\/CIRCULATIONAHA.108.808733","volume":"119","author":"E Hagstr\u00f6m","year":"2009","unstructured":"Hagstr\u00f6m E et al (2009) Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119:2765\u20132771","journal-title":"Circulation"},{"key":"672_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/00019501-199809080-00007","volume":"9","author":"Y Arad","year":"1998","unstructured":"Arad Y, Spadaro LA, Roth M, Scordo J, Goodman K, Sherman S, Lerner G, Newstein D, Guerci AD (1998) Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications. An electron beam computed tomography study. Coron Artery Dis 9:513\u2013518","journal-title":"Coron Artery Dis"},{"key":"672_CR35","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.ehj.2003.09.010","volume":"24","author":"F Saleh","year":"2003","unstructured":"Saleh F (2003) Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24:2054\u20132060","journal-title":"Eur Heart J"},{"key":"672_CR36","doi-asserted-by":"crossref","unstructured":"Ogard CG, Engelmann MD, Kistorp C, Nielsen SL, Vestergaard H (2005) Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol 63(493\u2013498)","DOI":"10.1111\/j.1365-2265.2005.02363.x"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-019-0672-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11657-019-0672-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-019-0672-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:42:27Z","timestamp":1609548147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11657-019-0672-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1007\/s11657-019-0672-4","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"10"}}